We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.79 | -0.62% | 127.47 | 128.48 | 127.18 | 128.11 | 6,221,929 | 01:00:00 |
From May 2019 to May 2024
By Michael Dabaie
Agilent Technologies Inc. (A) said the U.S. Food and Drug Administration has approved the company's companion diagnostic PD-L1 IHC 22C3 pharmDx assay for expanded use.
The assay is now approved as an aid in identifying patients with Esophageal Squamous Cell Carcinoma for treatment with Keytruda, which is made by Merck & Co. Inc. (MRK).
This is the sixth cancer type for which PD-L1 IHC 22C3 pharmDx has gained FDA approval in the U.S., Agilent said. Agilent developed PD-L1 IHC 22C3 pharmDx in collaboration with Merck.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
July 31, 2019 15:00 ET (19:00 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
